New York Life Investment Management LLC acquired a new position in shares of Nkarta, Inc. (NASDAQ:NKTX – Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 134,592 shares of the company’s stock, valued at approximately $478,000. New York Life Investment Management LLC owned about 0.28% of Nkarta at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Gladius Capital Management LP acquired a new stake in shares of Nkarta during the 4th quarter worth about $28,000. Natixis acquired a new position in Nkarta in the 4th quarter valued at about $28,000. Advisor Group Holdings Inc. grew its position in Nkarta by 13,661.1% in the 4th quarter. Advisor Group Holdings Inc. now owns 4,954 shares of the company’s stock valued at $29,000 after acquiring an additional 4,918 shares in the last quarter. Quantbot Technologies LP grew its position in Nkarta by 39.1% in the 1st quarter. Quantbot Technologies LP now owns 3,200 shares of the company’s stock valued at $36,000 after acquiring an additional 900 shares in the last quarter. Finally, Federated Hermes Inc. grew its position in Nkarta by 735.3% in the 1st quarter. Federated Hermes Inc. now owns 4,711 shares of the company’s stock valued at $54,000 after acquiring an additional 4,147 shares in the last quarter. 86.66% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equities analysts have weighed in on the company. Stifel Nicolaus dropped their target price on Nkarta from $18.00 to $15.00 in a research report on Friday, August 11th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Nkarta in a research note on Friday, August 11th. Mizuho decreased their price objective on Nkarta from $26.00 to $15.00 and set a “buy” rating for the company in a research note on Monday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price objective (down previously from $19.00) on shares of Nkarta in a research note on Thursday, August 10th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Nkarta presently has an average rating of “Moderate Buy” and an average target price of $18.67.
Nkarta Stock Down 1.0 %
NKTX stock opened at $1.96 on Thursday. The business has a 50 day moving average price of $2.80 and a 200 day moving average price of $3.89. The stock has a market cap of $96.16 million, a price-to-earnings ratio of -0.77 and a beta of -0.12. Nkarta, Inc. has a fifty-two week low of $1.80 and a fifty-two week high of $17.66.
Nkarta (NASDAQ:NKTX – Get Free Report) last posted its earnings results on Thursday, August 10th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.01. As a group, sell-side analysts anticipate that Nkarta, Inc. will post -2.77 EPS for the current year.
Nkarta Profile
Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
See Also
- Five stocks we like better than Nkarta
- Technology Stocks Explained: Here’s What to Know About Tech
- 3 Ways to Play the Upcoming NFL Season
- What Are MATANA Stocks?
- The TJX Companies: Offprice Retail Hits its Stride in Q2
- What is a SEC Filing?
- Target Misses The Mark: Is It Too Late To Sell?
Want to see what other hedge funds are holding NKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nkarta, Inc. (NASDAQ:NKTX – Free Report).
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.
